Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
about
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer developmentPLK1, A Potential Target for Cancer TherapyA series of beta-carboline derivatives inhibit the kinase activity of PLKsCancer biomarker discovery: the entropic hallmark.A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative netwTowards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and HypoxiaPhase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignanciesA novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma.RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.The APC/C Ubiquitin Ligase: From Cell Biology to TumorigenesisA phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerCombined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cellsIdentifying Biomarkers and Drug Targets Using Systems Biology Approaches for Pancreatic CancerPhase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients.Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.Therapeutic relevance of the protein phosphatase 2A in cancer.The role of polo-like kinase 1 in carcinogenesis: cause or consequence?Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis.The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.CENPA overexpression promotes genome instability in pRb-depleted human cells.An enzoinformatics study targeting polo-like kinases-1 enzyme: Comparative assessment of anticancer potential of compounds isolated from leaves of Ageratum houstonianumThe balance of Polo-like kinase 1 in tumorigenesis.Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.Integrated analysis of tumor differentiation genes in pancreatic adenocarcinoma.Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma.Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer.
P2860
Q24650802-E6FECBA6-21C5-4B03-9B99-B43D9198A414Q26825016-3B7A0BB3-A004-40DF-BE9B-060AAB036204Q28078772-8B15F0E5-86E2-4D7E-A041-8ACFBFC98B0EQ28484219-646DC5FC-D439-46B0-9E33-078543F232F8Q30496149-B31620AE-447A-470F-AD64-6C1E22452825Q33401811-A32D1ACA-8643-4AF4-B316-FA2245C21BD9Q33820876-78DAA87B-A4F5-4D04-BE54-5266EB02B360Q34159739-B0EEE34D-3FA3-4C61-B65A-C09689BF9FC5Q34335982-CB89B0B8-5868-4181-BAD4-9F81AF02A504Q35222337-10707A81-803A-450E-96C9-D96389B60C47Q35540711-2540D339-52E5-4A0B-89CD-2C35D2B17EE5Q35886662-66CD0E65-25E6-4A93-A9C8-32EA8321ED17Q35971862-4676B5B5-311A-4FD7-8C71-F83143BA2B30Q36000183-45601E26-2B7D-4CA9-A414-211DDE9451A4Q36054290-C611F5D3-1A5C-429F-86F8-E1C5C6F047DBQ36312159-41E06E2D-2821-4C55-9EB0-F689E2BDB279Q36573921-74544C87-F5CE-462B-9F64-0E7AB3F6CC7DQ36776441-E498198D-CB8B-4B75-B992-6563E8B91D65Q36973076-5BDDFF5E-7A92-4D4C-B481-01673D470A17Q37335160-90B26517-D70A-485E-BF02-D1E039832AA0Q37398885-3FB95267-3938-4036-90ED-70665BCB1B21Q37641636-69C6CA7D-428B-4F96-AD47-887ABF10A48EQ38165149-1CF34427-6D10-44DF-9C62-255EB830012DQ38637013-66E9FB3F-D618-4D98-961E-B78F015985E0Q38671515-FD687F62-996A-4070-B94F-E97B1BD219E3Q38735556-B7406C3F-D54D-4976-B8E9-A2A2F2D165D5Q38989539-77EFF30D-C68B-4E4D-A1A6-4963037A8B31Q39764758-D678418A-CDDF-4CE5-985C-F790DAB5712FQ40376895-58666102-7039-4740-B02B-428E3D3BB661Q43180721-3AE6C061-7D73-4980-9B66-64B4F074B735Q47217912-6989F3F3-7139-4904-AD92-6826C0958FC0Q52723252-57B0C985-9B9B-4676-B5CE-172C48834181Q54979207-92641D2C-4461-4E64-9073-5F516F477679Q55504441-11E26668-A2CA-484B-8BC4-5839ABBC5B29
P2860
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Identification of human polo-l ...... c target in pancreatic cancer.
@en
type
label
Identification of human polo-l ...... c target in pancreatic cancer.
@en
prefLabel
Identification of human polo-l ...... c target in pancreatic cancer.
@en
P2093
P1476
Identification of human polo-l ...... c target in pancreatic cancer.
@en
P2093
Daniel D Von Hoff
David J Bearss
Haiyong Han
Ming-Sound Tsao
Nicholas Dean
Phillip J Gray
Raymond Nagle
P304
P577
2004-05-01T00:00:00Z